Profund Advisors’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$734K Sell
17,190
-16
-0.1% -$869 0.02% 426
2026
Q1
$1.08M Sell
17,206
-8,063
-32% -$645K 0.04% 329
2025
Q4
$2.41M Buy
25,269
+4,542
+22% +$445K 0.07% 180
2025
Q3
$2.02M Sell
20,727
-2,413
-10% -$250K 0.07% 189
2025
Q2
$2.49M Buy
23,140
+2,062
+10% +$209K 0.09% 150
2025
Q1
$2.13M Sell
21,078
-1,779
-8% -$179K 0.09% 165
2024
Q4
$2.04M Sell
22,857
-446
-2% -$39.3K 0.07% 180
2024
Q3
$1.95M Buy
23,303
+166
+0.7% +$13.1K 0.07% 191
2024
Q2
$1.78M Sell
23,137
-44
-0.2% -$3.22K 0.07% 192
2024
Q1
$1.59M Sell
23,181
-340
-1% -$21.9K 0.06% 211
2023
Q4
$1.36M Buy
23,521
+945
+4% +$50.4K 0.06% 266
2023
Q3
$1.19M Buy
22,576
+10
+0% +$524 0.07% 245
2023
Q2
$1.22M Buy
22,566
+629
+3% +$32.9K 0.07% 272
2023
Q1
$1.1M Sell
21,937
-1,564
-7% -$73.7K 0.07% 279
2022
Q4
$1.09M Buy
23,501
+1,478
+7% +$64K 0.07% 253
2022
Q3
$853K Sell
22,023
-1,622
-7% -$65.1K 0.06% 270
2022
Q2
$881K Sell
23,645
-2,747
-10% -$112K 0.06% 286
2022
Q1
$1.17M Sell
26,392
-2,574
-9% -$112K 0.05% 284
2021
Q4
$1.23M Buy
28,966
+915
+3% +$38.4K 0.04% 282
2021
Q3
$1.22M Buy
28,051
+235
+0.8% +$10.4K 0.04% 300
2021
Q2
$1.19M Buy
27,816
+255
+0.9% +$10.7K 0.04% 307
2021
Q1
$1.06M Sell
27,561
-1,799
-6% -$68.1K 0.04% 298
2020
Q4
$1.05M Sell
29,360
-2,965
-9% -$107K 0.05% 303
2020
Q3
$1.24M Sell
32,325
-8,097
-20% -$312K 0.06% 242
2020
Q2
$1.42M Buy
40,422
+10,116
+33% +$364K 0.08% 215
2020
Q1
$989K Sell
30,306
-9,027
-23% -$353K 0.07% 236
2019
Q4
$1.78M Buy
39,333
+3,143
+9% +$132K 0.08% 235
2019
Q3
$1.47M Sell
36,190
-4,859
-12% -$206K 0.07% 246
2019
Q2
$1.76M Sell
41,049
-10,501
-20% -$404K 0.08% 230
2019
Q1
$1.98M Buy
51,550
+4,157
+9% +$159K 0.1% 196
2018
Q4
$1.68M Sell
47,393
-11,424
-19% -$414K 0.1% 188
2018
Q3
$2.26M Buy
58,817
+14,952
+34% +$522K 0.09% 199
2018
Q2
$1.43M Sell
43,865
-4,630
-10% -$140K 0.06% 271
2018
Q1
$1.32M Sell
48,495
-1,134
-2% -$30.8K 0.05% 309
2017
Q4
$1.23M Sell
49,629
-15,180
-23% -$419K 0.05% 376
2017
Q3
$1.89M Buy
64,809
+4,071
+7% +$112K 0.08% 238
2017
Q2
$1.68M Buy
60,738
+4,694
+8% +$125K 0.08% 235
2017
Q1
$1.39M Buy
56,044
+7,423
+15% +$180K 0.06% 300
2016
Q4
$1.05M Sell
48,621
-5,400
-10% -$118K 0.05% 401
2016
Q3
$1.29M Sell
54,021
-2,426
-4% -$57.9K 0.06% 291
2016
Q2
$1.32M Sell
56,447
-7,660
-12% -$166K 0.06% 272
2016
Q1
$1.21M Sell
64,107
-12,138
-16% -$213K 0.06% 283
2015
Q4
$1.41M Sell
76,245
-6,845
-8% -$123K 0.07% 241
2015
Q3
$1.36M Sell
83,090
-26,778
-24% -$458K 0.08% 209
2015
Q2
$1.95M Buy
109,868
+8,628
+9% +$154K 0.08% 180
2015
Q1
$1.8M Buy
101,240
+3,009
+3% +$47.6K 0.07% 236
2014
Q4
$1.3M Buy
98,231
+15,390
+19% +$197K 0.05% 330
2014
Q3
$978K Buy
82,841
+15,479
+23% +$195K 0.05% 393
2014
Q2
$860K Sell
67,362
-11,429
-15% -$149K 0.04% 566
2014
Q1
$1.06M Buy
78,791
+8,213
+12% +$108K 0.05% 429
2013
Q4
$848K Buy
70,578
+3,487
+5% +$41.2K 0.04% 632
2013
Q3
$788K Buy
67,091
+3,807
+6% +$41.2K 0.04% 597
2013
Q2
$587K Buy
+63,284
New +$537K 0.04% 534

Other funds holding BSX

Profund Advisors's BSX Position: Q2 2026 in Review

Profund Advisors reduced its Boston Scientific (BSX) stake by 0.09% in Q2 2026, selling an estimated $869 and leaving 17,190 shares worth $734K. The position accounts for 0.02% of the portfolio, ranked #426.

Profund Advisors first reported a position in BSX in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.49M in Q2 2025. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Profund Advisors held 17,190 shares of Boston Scientific worth $734K as of Q2 2026.
  • Profund Advisors sold 16 Boston Scientific shares in Q2 2026, an estimated $869.
  • Boston Scientific made up 0.02% of Profund Advisors's portfolio in Q2 2026, its #426 holding.
  • Profund Advisors first reported a position in Boston Scientific in Q2 2013 and has held it in 53 quarters since.
  • Profund Advisors's Boston Scientific position peaked at $2.49M in Q2 2025.
  • 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.